BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Aung W, Tsuji AB, Sudo H, Sugyo A, Ukai Y, Kouda K, Kurosawa Y, Furukawa T, Saga T, Higashi T. Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor. World J Gastroenterol 2017; 23(42): 7551-7562 [PMID: 29204055 DOI: 10.3748/wjg.v23.i42.7551]
URL: https://www.wjgnet.com/1007-9327/full/v23/i42/7551.htm
Number Citing Articles
1
Atsushi B. Tsuji, Tsuneo Saga. Cancer Drug Delivery Systems Based on the Tumor Microenvironment2019; : 289 doi: 10.1007/978-4-431-56880-3_13
2
Ashleigh Hull, Yanrui Li, Dylan Bartholomeusz, William Hsieh, Barry Allen, Eva Bezak. Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of LiteratureCancers 2020; 12(2): 481 doi: 10.3390/cancers12020481
3
Le Yu, Jessica Wei, Pengda Liu. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancerSeminars in Cancer Biology 2021;  doi: 10.1016/j.semcancer.2021.06.019
4
Cédric Leroux, Georgia Konstantinidou. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized OncologyCancers 2021; 13(4): 799 doi: 10.3390/cancers13040799